Citations (119)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (31)
Hirotaka Watada, Toshimasa Yamauchi, Fumiko Yamamoto, Atsushi Taniguchi, Larisa Yarush, Clemens Heilmann & Atsutaka Yasui. (2020) Safety and tolerability of empagliflozin and linagliptin combination therapy in patients with type 2 diabetes mellitus: a pooled analysis of data from five randomized, controlled clinical trials. Expert Opinion on Drug Safety 19:9, pages 1193-1202.
Read now
Read now
Yoshifumi Saisho. (2020) An emerging new concept for the management of type 2 diabetes with a paradigm shift from the glucose-centric to beta cell-centric concept of diabetes - an Asian perspective. Expert Opinion on Pharmacotherapy 21:13, pages 1565-1577.
Read now
Read now
Ildiko Lingvay, Nadine Beetz, Regina Sennewald, Annette Schuler-Metz, Julia Bertulis, Christina Loley, Benjamin Lang, Caroline Lippert, Jisoo Lee, Linda Shapiro Manning & Derek Terada. (2020) Triple fixed-dose combination empagliflozin, linagliptin, and metformin for patients with type 2 diabetes. Postgraduate Medicine 132:4, pages 337-345.
Read now
Read now
Elizabeth Mary Lamos, Maka Hedrington & Stephen N Davis. (2019) An update on the safety and efficacy of oral antidiabetic drugs: DPP-4 inhibitors
and SGLT-2 inhibitors. Expert Opinion on Drug Safety 18:8, pages 691-701.
Read now
Read now
Hong Yu, Li Ming Lim, Bingxue Dong & Kunn Hadinoto. (2019) Proof-of-concept preparation and characterization of dual-drug amorphous nanoparticle complex as fixed-dose combination of poorly soluble drugs. Drug Development and Industrial Pharmacy 45:1, pages 105-116.
Read now
Read now
Godfrey Mutashambara Rwegerera, Thato Moshomo, Marea Gaenamong, Taibat Aderonke Oyewo, Sivasomnath Gollakota, Francis Apolinary Mhimbira, Joseph Fadare, Brian Godman, Johanna C. Meyer & Yordanka Piña Rivera. (2018) RETRACTED ARTICLE: Antidiabetic medication adherence and associated factors among patients in Botswana; implications for the future. Alexandria Journal of Medicine 54:2, pages 103-109.
Read now
Read now
Christos V. Rizos, Theodosios D. Filippatos & Moses S. Elisaf. (2018) Pharmacokinetic drug evaluation of empagliflozin plus linagliptin for the treatment of type 2 diabetes. Expert Opinion on Drug Metabolism & Toxicology 14:1, pages 117-125.
Read now
Read now
Danilo D. Trevisan, Thaís M. São-João, Marilia E. Cornélio, Fernanda F. Jannuzzi, Roberta C. M. Rodrigues & Maria Helena M. Lima. (2017) A randomized controlled trial on the effect of behavioral strategies for adherence to oral antidiabetic drugs: study protocol. Contemporary Nurse 53:6, pages 658-668.
Read now
Read now
Jayant Dey. (2017) SGLT2 inhibitor/DPP-4 inhibitor combination therapy – complementary mechanisms of action for management of type 2 diabetes mellitus. Postgraduate Medicine 129:4, pages 409-420.
Read now
Read now
Jingbo Hu, Ping Zou, Shuo Zhang, Minzhi Zhou & Xueying Tan. (2016) Empagliflozin/metformin fixed-dose combination: a review in patients with type 2 diabetes. Expert Opinion on Pharmacotherapy 17:18, pages 2471-2477.
Read now
Read now
Catherine M Kuecker & Eva M Vivian. (2016) Patient considerations in type 2 diabetes – role of combination dapagliflozin–metformin XR. Diabetes, Metabolic Syndrome and Obesity 9, pages 25-35.
Read now
Read now
Stuart A. Ross, A. Enrique Caballero, Stefano Del Prato, Baptist Gallwitz, Diane Lewis-D’Agostino, Zelie Bailes, Sandra Thiemann, Sanjay Patel, Hans-Juergen Woerle & Maximilian von Eynatten. (2016) Linagliptin plus metformin in patients with newly diagnosed type 2 diabetes and marked hyperglycemia. Postgraduate Medicine 128:8, pages 747-754.
Read now
Read now
Stewart B. Harris. (2016) The power of two: an update on fixed-dose combinations for type 2 diabetes. Expert Review of Clinical Pharmacology 9:11, pages 1453-1462.
Read now
Read now
Suhaj Abdulsalim, Munawar Peringadi Vayalil & Sonal Sekhar Miraj. (2016) New fixed dose chemical combinations: the way forward for better diabetes type II management?. Expert Opinion on Pharmacotherapy 17:16, pages 2207-2214.
Read now
Read now
Tasneem Lokhandwala, Nancy Smith, Catarina Sternhufvud, Elisabeth Sörstadius, Won Chan Lee & Jayanti Mukherjee. (2016) A retrospective study of persistence, adherence, and health economic outcomes of fixed-dose combination vs loose-dose combination of oral anti-diabetes drugs. Journal of Medical Economics 19:3, pages 203-212.
Read now
Read now
David S. H. Bell. (2016) Aspirin in the prevention of cardiovascular events in patients with diabetes. Postgraduate Medicine 128:2, pages 180-190.
Read now
Read now
Xueying Tan & Jingbo Hu. (2016) Combination therapy for type 2 diabetes: dapagliflozin plus metformin. Expert Opinion on Pharmacotherapy 17:1, pages 117-126.
Read now
Read now
Yoshifumi Saisho. (2015) Alogliptin benzoate for management of type 2 diabetes. Vascular Health and Risk Management 11, pages 229-243.
Read now
Read now
Joshua W Fleming, Laurie W Fleming & Courtney S Davis. (2015) Fixed-dose combinations in type 2 diabetes – role of the canagliflozin metformin combination. Diabetes, Metabolic Syndrome and Obesity 8, pages 287-294.
Read now
Read now
Frank Lavernia, Sarah E. Adkins & Jay H. Shubrook. (2015) Use of oral combination therapy for type 2 diabetes in primary care: Meeting individualized patient goals. Postgraduate Medicine 127:8, pages 808-817.
Read now
Read now
Devada Singh-Franco. (2015) Potential for dipeptidyl peptidase-4 inhibitor and sodium glucose cotransporter 2 inhibitor single-pill combinations. Expert Review of Endocrinology & Metabolism 10:3, pages 305-317.
Read now
Read now
Ronnie Aronson. (2015) Single-pill combination therapy for type 2 diabetes mellitus: linagliptin plus empagliflozin. Current Medical Research and Opinion 31:5, pages 901-911.
Read now
Read now
Stanley S. Schwartz. (2013) A practice-based approach to the 2012 position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Current Medical Research and Opinion 29:7, pages 793-799.
Read now
Read now
Niki Katsiki, Vasilios G. Athyros & Asterios Karagiannis. (2013) Single-pill combinations: a therapeutic option or necessity for vascular risk treatment?. Journal of Drug Assessment 2:1, pages 67-71.
Read now
Read now
André J Scheen. (2013)
Linagliptin plus metformin: a pharmacokinetic and pharmacodynamic evaluation. Expert Opinion on Drug Metabolism & Toxicology 9:3, pages 363-377.
Read now
Read now
André J Scheen. (2013) Efficacy and safety of Jentadueto® (linagliptin plus metformin). Expert Opinion on Drug Safety 12:2, pages 275-289.
Read now
Read now
Stuart A. Ross, Elizabeth Rafeiro, Thomas Meinicke, Robert Toorawa, Sonja Weber-Born & Hans-Juergen Woerle. (2012) Efficacy and safety of linagliptin 2.5 mg twice daily versus 5 mg once daily in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, placebo-controlled trial. Current Medical Research and Opinion 28:9, pages 1465-1474.
Read now
Read now
André J Scheen. (2012) Pharmacokinetic evaluation of atorvastatin and sitagliptin in combination for the treatment of type 2 diabetes. Expert Opinion on Drug Metabolism & Toxicology 8:6, pages 745-758.
Read now
Read now
Steven Han, Kristy Iglay, Michael J. Davies, Qiaoyi Zhang & Larry Radican. (2012) Glycemic effectiveness and medication adherence with fixed-dose combination or coadministered dual therapy of antihyperglycemic regimens: a meta-analysis. Current Medical Research and Opinion 28:6, pages 969-977.
Read now
Read now
André J Scheen. (2012) Saxagliptin plus metformin combination therapy. Expert Review of Endocrinology & Metabolism 7:2, pages 151-164.
Read now
Read now
Wei Zhang, Shan-Shan Xing, Huan-Jun Wang & Qi-Chong Xing. (2011) Fixed-dose single tablet combinations: an alternative for initial therapy of patients with Type 2 diabetes?. Current Medical Research and Opinion 27:12, pages 2321-2322.
Read now
Read now
Articles from other publishers (88)
Xiaoying Zhao, Rui Ning, Andrew Hui, David W. Boulton & Weifeng Tang. (2023) Pharmacokinetic Variables of Dapagliflozin/Metformin Extended-Release Fixed-Dose Combination in Healthy Chinese Volunteers and Regional Comparison. Clinical Therapeutics.
Crossref
Crossref
E. V. Biryukova & D. V. Kileynikov. (2023) Metformin and sitagliptin fixed combination as the optimal choice in solving current problems in the type 2 diabetes mellitus treatment. Meditsinskiy sovet = Medical Council 17:9, pages 23-30.
Crossref
Crossref
Jean-François Yale, Aude Roborel de Climens, Naresh Aggarwal, Terry Dex, Hertzel C. Gerstein, Stewart Harris, Irene Hramiak, John Stewart & Lawrence A. Leiter. (2022) Ease of Use of the iGlarLixi SoloStar Pen from the LixiLan ONE CAN Pen Sub-Study: Questionnaire Findings from People Living with Type 2 Diabetes and Their HealthCare Providers. Diabetes Therapy 14:2, pages 377-386.
Crossref
Crossref
Yvonne Schnaars, Sumedh Gaikwad, Ulrike Gottwald-Hostalek, Wolfgang Uhl, Olga Ribot, Kanthikiran V. S. Varanasi, Laura Rodríguez, Javier Torrejón & Luis Gómez. (2022) Bioequivalence Evaluation in Healthy Volunteers: New Generic Formulations of Sitagliptin and Sitagliptin–Metformin Fixed-Dose Combination Compared with the Originator Products. Diabetes Therapy 14:2, pages 347-362.
Crossref
Crossref
António Cabral Lopes, Olga Lourenço, Fátima Roque & Manuel Morgado. (2023) Clinical and Pharmacotherapeutic Profile of Patients with Type 2 Diabetes Mellitus Admitted to a Hospital Emergency Department. Biomedicines 11:2, pages 256.
Crossref
Crossref
Nor Fadhilah Abdullah, Lee Khuan, Cheong Ai Theng & Siti Noorkhairina Sowtali. (2022) Prevalence and reasons influenced medication non-adherence among diabetes patients: A mixed-method study. Journal of Diabetes & Metabolic Disorders 21:2, pages 1669-1678.
Crossref
Crossref
Tomoya Mita, Naoto Katakami, Mitsuyoshi Takahara, Masaru Kawashima, Fumitaka Wada, Hiroki Akiyama, Naru Morita, Yoko Kidani, Toshitaka Yajima, Iichiro Shimomura & Hirotaka Watada. (2022) Changes in Treatment Satisfaction Over 3 Years in Patients With Type 2 Diabetes After Initiating Second-line Treatment. The Journal of Clinical Endocrinology & Metabolism 107:9, pages 2424-2432.
Crossref
Crossref
Yvonne Schnaars, Sumedh Gaikwad, Ulrike Gottwald-Hostalek, Ulrike Klingberg, Hari Kiran Chary Vadla & Vamshi Ramana Prathap. (2022) Bioequivalence Studies of New Generic Formulations of Vildagliptin and Fixed-Drug Combination of Vildagliptin and Metformin Versus Respective Originator Products in Healthy Volunteers. Diabetes Therapy 13:6, pages 1215-1229.
Crossref
Crossref
Takashi Kadowaki, Nobuya Inagaki, Hirotaka Watada, Kazuyo Sasaki, Kazumi Mori-Anai, Tomohisa Iwasaki & Tatsuki Teranishi. (2022) Real-World Evidence of Treatment with Teneligliptin/Canagliflozin Combination Tablets for Type 2 Diabetes Mellitus: A Post-Marketing Surveillance in Japan. Advances in Therapy 39:4, pages 1642-1658.
Crossref
Crossref
Ha Eun Choi, Ji Won Lee, Nam Kyung Je & Kyeong Hye Jeong. (2022) Use of SGLT2 inhibitor/metformin fixed dose combination in Korea. Korean Journal of Clinical Pharmacy 32:1, pages 13-19.
Crossref
Crossref
Jin-Woo Park, Jong-Min Kim, Ji Hyeon Noh, Kyoung-Ah Kim, Hyewon Chung, EunJi Kim, Minja Kang & Ji-Young Park. (2022) Pharmacokinetics of a Fixed-Dose Combination Product of Dapagliflozin and Linagliptin and Its Comparison with Co-Administration of Individual Tablets in Healthy Humans. Pharmaceutics 14:3, pages 591.
Crossref
Crossref
Eun Bin Seo, Lissinda H. du Plessis & Joe M. Viljoen. (2022) Solidification of Self-Emulsifying Drug Delivery Systems as a Novel Approach to the Management of Uncomplicated Malaria. Pharmaceuticals 15:2, pages 120.
Crossref
Crossref
Yasuyo Ando, Fumika Shigiyama, Takahisa Hirose & Naoki Kumashiro. (2021) Simplification of complex insulin regimens using canagliflozin or liraglutide in patients with well‐controlled type 2 diabetes: A 24‐week randomized controlled trial. Journal of Diabetes Investigation 12:10, pages 1816-1826.
Crossref
Crossref
Massimo Genovese, Ilaria Nesi, Anna Caselli & Paolo Paoli. (2021) Natural α-Glucosidase and Protein Tyrosine Phosphatase 1B Inhibitors: A Source of Scaffold Molecules for Synthesis of New Multitarget Antidiabetic Drugs. Molecules 26:16, pages 4818.
Crossref
Crossref
Laila Carolina Abu Esba, Consuela Yousef, Sherine Ismail, Murtada Halim, Hind Almodaimegh, Hana Abdullah Al-Abdulkarim & Mansour Alhowimel. (2021) Fixed dose combinations: A formulary decision guide. Health Policy and Technology 10:2, pages 100500.
Crossref
Crossref
Anna-Katharina Böhm, Udo Schneider, Jens Aberle & Tom Stargardt. (2021) Regimen simplification and medication adherence: Fixed-dose versus loose-dose combination therapy for type 2 diabetes. PLOS ONE 16:5, pages e0250993.
Crossref
Crossref
Bisrat Desalegn Boshe, Getachew Nenko Yimar, Aberash Eifa Dadhi & Worku Ketema Bededa. (2021) The magnitude of non-adherence and contributing factors among adult outpatient with Diabetes Mellitus in Dilla University Referral Hospital, Gedio, Ethiopia. PLOS ONE 16:3, pages e0247952.
Crossref
Crossref
Ki Young Huh, Eunwoo Kim, Heechan Lee, Inseung Jeon, Hearan Suh, Jongsun Lee, Yunhee Lee, Kyung‐Sang Yu & SeungHwan Lee. (2020) Comparison of the Pharmacokinetics of a Fixed‐Dose Combination of Rosuvastatin/Metformin Sustained‐Release (10/1000 mg) and Separate Tablets in Healthy Male Subjects. Clinical Pharmacology in Drug Development 10:2, pages 207-213.
Crossref
Crossref
Jafer Siraj, Turi Abateka & Oliyad Kebede. (2021) Patients’ Adherence to Anti-diabetic Medications and Associated Factors in Mizan-Tepi University Teaching Hospital: A Cross-Sectional Study. INQUIRY: The Journal of Health Care Organization, Provision, and Financing 58, pages 004695802110674.
Crossref
Crossref
Gebre Teklemariam Demoz, Shishay Wahdey, Degena Bahrey, Halefom Kahsay, Gebremariam Woldu, Yirga Legesse Niriayo & Andrew Collier. (2020) Predictors of poor adherence to antidiabetic therapy in patients with type 2 diabetes: a cross-sectional study insight from Ethiopia. Diabetology & Metabolic Syndrome 12:1.
Crossref
Crossref
Philip Home, Lawrence Blonde, Sanjay Kalra, Linong Ji, Patricia Guyot, Claire Brulle‐Wohlhueter, Erin Murray, Roshan Shah, Toby Sayre & Alka Shaunik. (2020)
Insulin glargine/lixisenatide fixed‐ratio combination (
iGlarLixi
) compared with premix or addition of meal‐time insulin to basal insulin in people with type 2 diabetes: A systematic review and Bayesian network meta‐analysis
. Diabetes, Obesity and Metabolism 22:11, pages 2179-2188.
Crossref
Crossref
Natasha C. H. Ting, Nicole El-Turk, Michael S. H. Chou & Claudia C. Dobler. (2020) Patient-perceived treatment burden of tuberculosis treatment. PLOS ONE 15:10, pages e0241124.
Crossref
Crossref
Niki Katsiki, Richard Ofori‐Asenso, Ele Ferrannini & Mohsen Mazidi. (2020) Fixed‐dose combination of empagliflozin and linagliptin for the treatment of patients with type 2 diabetes mellitus: A systematic review and meta‐analysis. Diabetes, Obesity and Metabolism 22:6, pages 1001-1005.
Crossref
Crossref
Ana Baumgartner, Katarina Drame, Stijn Geutjens & Marja Airaksinen. (2020) Does the Polypill Improve Patient Adherence Compared to Its Individual Formulations? A Systematic Review. Pharmaceutics 12:2, pages 190.
Crossref
Crossref
Enrico Torre, Giacomo Matteo Bruno, Sergio Di Matteo, Chiara Martinotti, Maria Chiara Valentino, Luigi Carlo Bottaro & Giorgio Lorenzo Colombo. (2020) Cost-Utility Analysis of Saxagliptin/Dapagliflozin Versus Gliclazide and Insulin Glargine: Economic Implications of the Outcomes of the CVD-Real Studies I and II. Health Services Insights 13, pages 117863292092998.
Crossref
Crossref
Ádám G. Tabák, John Anderson, Pablo Aschner, Minzhi Liu, Aramesh Saremi, Peter Stella, Francisco J. Tinahones, Carol Wysham & Juris J. Meier. (2019) Efficacy and Safety of iGlarLixi, Fixed-Ratio Combination of Insulin Glargine and Lixisenatide, Compared with Basal-Bolus Regimen in Patients with Type 2 Diabetes: Propensity Score Matched Analysis. Diabetes Therapy 11:1, pages 305-318.
Crossref
Crossref
Devarajan Rathish, Ruvini Hemachandra, Thilini Premadasa, Sasini Ramanayake, Chathuri Rasangika, Ravi Roshiban & Channa Jayasumana. (2019) Comparison of medication adherence between type 2 diabetes mellitus patients who pay for their medications and those who receive it free: a rural Asian experience. Journal of Health, Population and Nutrition 38:1.
Crossref
Crossref
Leopold Ndemnge Aminde, Maxime Tindong, Calypse A. Ngwasiri, Jeannine A. Aminde, Tsi Njim, Azingala Ajua Fondong & Noah Fongwen Takah. (2019) Adherence to antidiabetic medication and factors associated with non-adherence among patients with type-2 diabetes mellitus in two regional hospitals in Cameroon. BMC Endocrine Disorders 19:1.
Crossref
Crossref
Nuhu Amin, Dawn D. Sagerman, Fosiul A. Nizame, Kishor K. Das, Md Nuruzzaman, Jihnhee Yu, Leanne Unicomb, Stephen P. Luby & Pavani K. Ram. (2019) Effects of complexity of handwashing instructions on handwashing procedure replication in low-income urban slums in Bangladesh: a randomized non-inferiority field trial. Journal of Water, Sanitation and Hygiene for Development 9:3, pages 416-428.
Crossref
Crossref
V. Katsi, G. Skalis, M.S. Kallistratos, K. Tsioufis, T. Makris, A.J. Manolis & D. Tousoulis. (2019) Ivabradine and metoprolol in fixed dose combination: When, why and how to use it. Pharmacological Research 146, pages 104279.
Crossref
Crossref
Robert Schlosser. (2019) Fixed-Dose and Fixed-Ratio Combination Therapies in Type 2 Diabetes. Canadian Journal of Diabetes 43:6, pages 440-444.
Crossref
Crossref
Weifeng Tang, Helena Engman, Yali Zhu, Brian Dayton & David W. Boulton. (2019) Bioequivalence and Food Effect of Dapagliflozin/Saxagliptin/Metformin Extended-release Fixed-combination Drug Products Compared With Coadministration of the Individual Components in Healthy Subjects. Clinical Therapeutics 41:8, pages 1545-1563.
Crossref
Crossref
Eleni Pappa, Christos V. Rizos, Theodosios D. Filippatos & Moses S. Elisaf. (2019) Emerging Fixed-Dose Combination Treatments for Hyperlipidemia. Journal of Cardiovascular Pharmacology and Therapeutics 24:4, pages 315-322.
Crossref
Crossref
Mai Sotoyama, Shinya Uchida, Chiaki Kamiya, Shimako Tanaka, Yasuharu Kashiwagura, Akio Hakamata, Keiichi Odagiri, Naoki Inui, Hiroshi Watanabe & Noriyuki Namiki. (2019) Ease of Taking and Palatability of Fixed-Dose Orally Disintegrating Mitiglinide/Voglibose Tablets. Chemical and Pharmaceutical Bulletin 67:6, pages 540-545.
Crossref
Crossref
Fernando Perez-Ruiz & Nicola Dalbeth. (2019) Combination urate-lowering therapy in the treatment of gout: What is the evidence?. Seminars in Arthritis and Rheumatism 48:4, pages 658-668.
Crossref
Crossref
N. A. PetuninaA. L. Terekhova. (2019) Reliable choice in therapy of type 2 diabetes mellitus: focus on alogliptin. Medical Council:21, pages 138-145.
Crossref
Crossref
Francesco Indovina, Pierpaolo Falcetta & Stefano Del Prato. (2018) Type 2 Diabetes Mellitus. From the start – combination therapy. Diabetes mellitus 21:5, pages 386-394.
Crossref
Crossref
Yeon-Yong Kim, Jin-Seok Lee, Hee-Jin Kang & Sang Min Park. (2018) Effect of medication adherence on long-term all-cause-mortality and hospitalization for cardiovascular disease in 65,067 newly diagnosed type 2 diabetes patients. Scientific Reports 8:1.
Crossref
Crossref
Hasniza Zaman Huri, Chua Chew Huey, Norasyikin Mustafa, Nor Fadhilah Mohamad & Tengku Ain Kamalden. (2018) Association of glycemic control with progression of diabetic retinopathy in type 2 diabetes mellitus patients in Malaysia. Brazilian Journal of Pharmaceutical Sciences 54:2.
Crossref
Crossref
Ralph A. DeFronzo, Christopher Lee & Sven Kohler. (2018) Safety and Tolerability of Combinations of Empagliflozin and Linagliptin in Patients with Type 2 Diabetes: Pooled Data from Two Randomized Controlled Trials. Advances in Therapy 35:7, pages 1009-1022.
Crossref
Crossref
Lawrence Blonde, Susana Dipp & Daniel Cadena. (2018) Combination Glucose-Lowering Therapy Plans in T2DM: Case-Based Considerations. Advances in Therapy 35:7, pages 939-965.
Crossref
Crossref
Kathleen N. Moore & Michael J. Birrer. (2018) Administration of the Tablet Formulation of Olaparib in Patients with Ovarian Cancer: Practical Guidance and Expectations. The Oncologist 23:6, pages 697-703.
Crossref
Crossref
Joseph Nwadiuko & Laura D Sander. (2018) Simplifying care: when is the treatment burden too much for patients living in poverty?. BMJ Quality & Safety 27:6, pages 484-487.
Crossref
Crossref
Yoshifumi Saisho. (2018) Use of Diabetes Treatment Satisfaction Questionnaire in Diabetes Care: Importance of Patient-Reported Outcomes. International Journal of Environmental Research and Public Health 15:5, pages 947.
Crossref
Crossref
Yunona Khomitskaya, Nadezhda Tikhonova, Konstantin Gudkov, Svetlana Erofeeva, Victoria Holmes, Brian Dayton, Nigel Davies, David W. Boulton & Weifeng Tang. (2018) Bioequivalence of Dapagliflozin/Metformin Extended-release Fixed-combination Drug Product and Single-component Dapagliflozin and Metformin Extended-release Tablets in Healthy Russian Subjects. Clinical Therapeutics 40:4, pages 550-561.e3.
Crossref
Crossref
Ranjeet Prasad Dash, Rana Rais & Nuggehally R. Srinivas. (2017) Key Pharmacokinetic Essentials of Fixed-Dosed Combination Products: Case Studies and Perspectives. Clinical Pharmacokinetics 57:4, pages 419-426.
Crossref
Crossref
Eugenio Cersosimo, Eric L. Johnson, Christina Chovanes & Neil Skolnik. (2018) Initiating therapy in patients newly diagnosed with type 2 diabetes: Combination therapy vs a stepwise approach. Diabetes, Obesity and Metabolism 20:3, pages 497-507.
Crossref
Crossref
Clare Bradley, Eveline Eschwège, Pedro de Pablos-Velasco, Klaus G. Parhofer, Dominique Simon, Hans Vandenberghe & Linda Gönder-Frederick. (2018) Predictors of Quality of Life and Other Patient-Reported Outcomes in the PANORAMA Multinational Study of People With Type 2 Diabetes. Diabetes Care 41:2, pages 267-276.
Crossref
Crossref
Sanjay Kalra, Silver Bahendeka, Rakesh Sahay, Sujoy Ghosh, Fariduddin Md, Abbas Orabi, Kaushik Ramaiya, Sameer Al Shammari, Dina Shrestha, Khalid Shaikh, Sachitha Abhayaratna, PradeepK Shrestha, Aravinthan Mahalingam, Mazen Askheta, AlyAhmed A. Rahim, Fatimah Eliana, HariK Shrestha, Sandeep Chaudhary, Nancy Ngugi, JeanClaude Mbanya, ThanThan Aye, TintSwe Latt, ZhanayA Akanov, AbbasRaza Syed, Nikhil Tandon, AG Unnikrishnan, SV Madhu, Ali Jawa, Subhankar Chowdhury, Sarita Bajaj & AshokKumar Das. (2018) Consensus recommendations on sulfonylurea and sulfonylurea combinations in the management of Type 2 diabetes mellitus – International Task Force. Indian Journal of Endocrinology and Metabolism 22:1, pages 132.
Crossref
Crossref
Jennifer D Goldman. (2018) Combination of Empagliflozin and Metformin Therapy: A Consideration of its Place in Type 2 Diabetes Therapy. Clinical Medicine Insights: Endocrinology and Diabetes 11, pages 117955141878625.
Crossref
Crossref
Valerie Azzopardi Coppenrath & Tasmina Hydery. (2017) Dapagliflozin/Saxagliptin Fixed-Dose Tablets: A New Sodium-Glucose Cotransporter 2 and Dipeptidyl Peptidase 4 Combination for the Treatment of Type 2 Diabetes. Annals of Pharmacotherapy 52:1, pages 78-85.
Crossref
Crossref
Aika Miya, Akinobu Nakamura, Hideaki Miyoshi, Kyu Yong Cho, So Nagai, Yoshio Kurihara, Shin Aoki, Masataka Taguri, Yasuo Terauchi & Tatsuya Atsumi. (2017) Satisfaction of switching to combination therapy with lixisenatide and basal insulin in patients with type 2 diabetes receiving multiple daily insulin injection therapy: A randomized controlled trial. Journal of Diabetes Investigation 9:1, pages 119-126.
Crossref
Crossref
Naoko Ogawa, Mitsuyoshi Takahara, Toshihiko Shiraiwa, Mayumi Yamamoto, Kaoru Yamamoto, Masayuki Doi, Yoko Yoshida & Setsuko Gotou. (2017) Improved treatment satisfaction and medication adherence after readjusting oral medication regimens with the cooperation of health insurance pharmacy in type 2 diabetic patients in Japan. Journal of Pharmaceutical Health Care and Sciences 3:1.
Crossref
Crossref
Wei-Min Chu, Hsin-En Ho, Kuang-Hua Huang, Yu-Tse Tsan, Yi-Sheng Liou, Yueh-Hsin Wang, Meng-Chih Lee & Yu-Ching Li. (2017) The prescribing trend of oral antidiabetic agents for type 2 diabetes in Taiwan. Medicine 96:43, pages e8257.
Crossref
Crossref
Ildiko Lingvay. (2017) Sodium Glucose Cotransporter 2 and Dipeptidyl Peptidase-4 Inhibition: Promise of a Dynamic Duo. Endocrine Practice 23:7, pages 831-840.
Crossref
Crossref
Zachary T. Bloomgarden, Kaan Tunceli, Jinan Liu, Kimberly G. Brodovicz, Panagiotis Mavros, Samuel S. Engel, Larry Radican, Yong Chen, Swapnil Rajpathak, Ying Qiu, Philippe Brudi & Vivian Fonseca. (2017) Adherence, persistence, and treatment discontinuation with sitagliptin compared with sulfonylureas as add-ons to metformin: A retrospective cohort database study. Journal of Diabetes 9:7, pages 677-688.
Crossref
Crossref
Aymen Elsous, Mahmoud Radwan, Hasnaa Al-Sharif & Ayman Abu Mustafa. (2017) Medications Adherence and Associated Factors among Patients with Type 2 Diabetes Mellitus in the Gaza Strip, Palestine. Frontiers in Endocrinology 8.
Crossref
Crossref
Jaime A. Davidson & Lance Sloan. (2016) Fixed-Dose Combination of Canagliflozin and Metformin for the Treatment of Type 2 Diabetes: An Overview. Advances in Therapy 34:1, pages 41-59.
Crossref
Crossref
Joel Zonszein & Per-Henrik Groop. (2016) Strategies for Diabetes Management: Using Newer Oral Combination Therapies Early in the Disease. Diabetes Therapy 7:4, pages 621-639.
Crossref
Crossref
Samuel StolpeMichel A. KroesNeil WebbTami Wisniewski. (2016) A Systematic Review of Insulin Adherence Measures in Patients with Diabetes. Journal of Managed Care & Specialty Pharmacy 22:11, pages 1224-1246.
Crossref
Crossref
Varun Vaidya, Vamshi Ruthwik Anupindi, Sharrel Pinto & Megan Kaun. (2016) Cost utility analysis of fixed-dose and free-dose combinations of oral medications in type 2 diabetes patients. Journal of Pharmaceutical Health Services Research 7:3, pages 181-187.
Crossref
Crossref
Michael Albrecht Nauck, Maximiliano di Domenico, Sanjay Patel, Maureen Kobe, Robert Toorawa & Hans-Juergen Woerle. (2016) Linagliptin and pioglitazone combination therapy versus monotherapy with linagliptin or pioglitazone: A randomised, double-blind, parallel-group, multinational clinical trial. Diabetes and Vascular Disease Research 13:4, pages 286-298.
Crossref
Crossref
. (2016) Parte III. Control clínico del tratamiento con fenofibrato. Clínica e Investigación en Arteriosclerosis 28, pages 20-25.
Crossref
Crossref
Shripad D. Chitnis, Yi Han, Masayuki Yamaguchi, Sachiko Mita, Rong Zhao, Gangadhar Sunkara & Kenneth Kulmatycki. (2016) Population pharmacokinetic modeling and noncompartmental analysis demonstrated bioequivalence between metformin component of metformin/vildagliptin fixed-dose combination products and metformin immediate-release tablet sourced from various countries. Clinical Pharmacology in Drug Development 5:1, pages 40-51.
Crossref
Crossref
James Bagonza, Elizeus Rutebemberwa & William Bazeyo. (2015) Adherence to anti diabetic medication among patients with diabetes in eastern Uganda; a cross sectional study. BMC Health Services Research 15:1.
Crossref
Crossref
V. Woo. (2015) Empagliflozin/linagliptin single‐tablet combination: first‐in‐class treatment option. International Journal of Clinical Practice 69:12, pages 1427-1437.
Crossref
Crossref
Blisse Vakkalagadda, Marion L. Vetter, Jignasa Rana, Charles H. Smith, Jian Huang, Jennifer Karkas, David W. Boulton & Frank LaCreta. (2016) Bioequivalence of saxagliptin/dapagliflozin fixed‐dose combination tablets compared with coadministration of the individual tablets to healthy subjects. Pharmacology Research & Perspectives 3:6.
Crossref
Crossref
Jorge Duconge & Gualberto Ruaño. (2015) Fixed-dose combination products and unintended drug interactions: urgent need for pharmacogenetic evaluation. Pharmacogenomics 16:15, pages 1685-1688.
Crossref
Crossref
Sreeraj Macha, Tobias Brand, Thomas Meinicke, Jasmin Link & Uli C. Broedl. (2015) Pharmacokinetics and Pharmacodynamics of Twice Daily and Once Daily Regimens of Empagliflozin in Healthy Subjects. Clinical Therapeutics 37:8, pages 1789-1796.
Crossref
Crossref
Francesca Brundisini, Meredith Vanstone, Danielle Hulan, Deirdre DeJean & Mita Giacomini. (2015) Type 2 diabetes patients’ and providers’ differing perspectives on medication nonadherence: a qualitative meta-synthesis. BMC Health Services Research 15:1.
Crossref
Crossref
Masato Odawara, Mika Yoshiki, Misako Sano, Izumi Hamada, Valentina Lukashevich & Wolfgang Kothny. (2015) Efficacy and Safety of a Single-Pill Combination of Vildagliptin and Metformin in Japanese Patients with Type 2 Diabetes Mellitus: A Randomized, Double-Blind, Placebo-Controlled Trial. Diabetes Therapy 6:1, pages 17-27.
Crossref
Crossref
S. A. Ross, A. E. Caballero, S. Del Prato, B. Gallwitz, D. Lewis‐D'Agostino, Z. Bailes, S. Thiemann, S. Patel, H.‐J. Woerle & M. von Eynatten. (2014) Initial combination of linagliptin and metformin compared with linagliptin monotherapy in patients with newly diagnosed type 2 diabetes and marked hyperglycaemia: a randomized, double‐blind, active‐controlled, parallel group, multinational clinical trial. Diabetes, Obesity and Metabolism 17:2, pages 136-144.
Crossref
Crossref
M. Chris Runken, Bridgett Goodwin, Manan Shah, Michael Eaddy, Anna D’Souza, Brian Bowers & Christopher F. Bell. (2014) Migraine-Related Healthcare Resource Use and Costs for Subjects Prescribed Fixed-Dose Combination Sumatriptan/Naproxen Sodium vs. Single-Entity Oral Triptans in a Managed Care Population in the USA. Applied Health Economics and Health Policy 13:1, pages 109-120.
Crossref
Crossref
Thomas Haak. (2015) Combination of Linagliptin and Metformin for the Treatment of Patients with Type 2 Diabetes. Clinical Medicine Insights: Endocrinology and Diabetes 8, pages CMED.S10360.
Crossref
Crossref
Yvonne Gautam, Ole J. Bjerrum & Merete Schmiegelow. (2015) The Wider Use of Fixed-Dose Combinations Emphasizes the Need for a Global Approach to Regulatory Guideline Development. Therapeutic Innovation & Regulatory Science 49:1, pages 197-204.
Crossref
Crossref
Grigorios Rombopoulos, Magdalini Hatzikou, Athanasios Athanasiadis & Moyses Elisaf. (2015) Treatment Compliance with Fixed-Dose Combination of Vildagliptin/Metformin in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Metformin Monotherapy: A 24-Week Observational Study. International Journal of Endocrinology 2015, pages 1-5.
Crossref
Crossref
Domingo Orozco-Beltrán, Concepción Carratalá-Munuera & Vicente Gil-Guillén. (2015) Mejorar la adherencia: una de las acciones más eficientes para aumentar la supervivencia de los pacientes en prevención secundaria. Revista Española de Cardiología Suplementos 15, pages 12-18.
Crossref
Crossref
Lawrence Blonde, Zinnia T. San Juan & Peggy Bolton. (2014) Fixed-Dose Combination Therapy in Type 2 Diabetes Mellitus. Endocrine Practice 20:12, pages 1322-1332.
Crossref
Crossref
O. J. Phung, D. M. Sobieraj, S. S. Engel & S. N. Rajpathak. (2014) Early combination therapy for the treatment of type 2 diabetes mellitus: systematic review and meta-analysis. Diabetes, Obesity and Metabolism 16:5, pages 410-417.
Crossref
Crossref
Jaime A. Davidson. (2013) Incretin-Based Therapies: Focus on Effects Beyond Glycemic Control Alone. Diabetes Therapy 4:2, pages 221-238.
Crossref
Crossref
Luis-Emilio García-Pérez, María Álvarez, Tatiana Dilla, Vicente Gil-Guillén & Domingo Orozco-Beltrán. (2013) Adherence to Therapies in Patients with Type 2 Diabetes. Diabetes Therapy 4:2, pages 175-194.
Crossref
Crossref
Lucas N. Marzec & Thomas M. Maddox. (2013) Medication Adherence in Patients with Diabetes and Dyslipidemia: Associated Factors and Strategies for Improvement. Current Cardiology Reports 15:11.
Crossref
Crossref
Jun-Sing Wang, Chien-Ning Huang, Yi-Jen Hung, Ching-Fai Kwok, Jui-Hung Sun, Dee Pei, Chwen-Yi Yang, Ching-Chu Chen, Ching-Ling Lin & Wayne Huey-Herng Sheu. (2013) Acarbose plus metformin fixed-dose combination outperforms acarbose monotherapy for type 2 diabetes. Diabetes Research and Clinical Practice 102:1, pages 16-24.
Crossref
Crossref
Stuart A. Ross. (2013) Breaking Down Patient and Physician Barriers to Optimize Glycemic Control in Type 2 Diabetes. The American Journal of Medicine 126:9, pages S38-S48.
Crossref
Crossref
D. S. H. Bell. (2012) Combine and conquer: advantages and disadvantages of fixed‐dose combination therapy. Diabetes, Obesity and Metabolism 15:4, pages 291-300.
Crossref
Crossref
Shinzo HiroiKenkichi SugiuraKumi MatsunoMasashi HirayamaKenji KuriyamaKohei KakuKoji Kawakami. (2013) A Multicenter, Phase III Evaluation of the Efficacy and Safety of a New Fixed-Dose Pioglitazone/Glimepiride Combination Tablet in Japanese Patients with Type 2 Diabetes. Diabetes Technology & Therapeutics 15:2, pages 158-165.
Crossref
Crossref
Emilio Márquez Contreras. (2012) El incumplimiento en el tratamiento de la diabetes mellitus tipo 2 en España. Hipertensión y Riesgo Vascular 29, pages 8-13.
Crossref
Crossref
Mike Benford, Gary Milligan, James Pike, Peter Anderson, James Piercy & Steve Fermer. (2012) Fixed-Dose Combination Antidiabetic Therapy: Real-World Factors Associated with Prescribing Choices and Relationship with Patient Satisfaction and Compliance. Advances in Therapy 29:1, pages 26-40.
Crossref
Crossref